2 research outputs found
Modificación hidrotérmica del almidón de yuca para su empleo como estabilizador de helados
En el trabajo se desarrolla un procedimiento de modificación física de almidón nativo de yuca a través de un tratamiento hidrotérmico en la zona previa a la gelatinización, de la cual no existen reportes de experimentación. El objetivo es determinar la influencia de las principales variables del proceso sobre el comportamiento reológico, con el propósito de ser empleado como estabilizador en la Industria heladera. Se alcanzaron buenos resultados reológicos con una concentración de 6% p/p de almidón nativo a 56 0C. El material obtenido se usó en formulaciones de helados, sustituyendo parte de los productos convencionales con efectos muy positivos en cuanto a la evaluación sensorial y el índice de aireación. Los resultados alcanzados permiten establecer perspectivas para el empleo de almidones modificados de yuca cuyo tratamiento hidrotérmico en la zona previa a la gelatinización ofrece efectos positivos, como estabilizante de suspensiones acuosas, similares a los que se alcanzan con almidones pregelatinizados, además con la ventaja de obtener el producto modificado con mayor facilidad
Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone
BACKGROUND:
The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate.
METHODS:
In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in the year before randomization but not during the previous month. Patients were excluded from the trial if they had a history of life-threatening or unstable asthma. The primary safety end point was the first serious asthma-related event (death, endotracheal intubation, or hospitalization). Noninferiority of fluticasone-salmeterol to fluticasone alone was defined as an upper boundary of the 95% confidence interval for the risk of the primary safety end point of less than 2.0. The efficacy end point was the first severe asthma exacerbation.
RESULTS:
Of 11,679 patients who were enrolled, 67 had 74 serious asthma-related events, with 36 events in 34 patients in the fluticasone-salmeterol group and 38 events in 33 patients in the fluticasone-only group. The hazard ratio for a serious asthma-related event in the fluticasone-salmeterol group was 1.03 (95% confidence interval [CI], 0.64 to 1.66), and noninferiority was achieved (P=0.003). There were no asthma-related deaths; 2 patients in the fluticasone-only group underwent asthma-related intubation. The risk of a severe asthma exacerbation was 21% lower in the fluticasone-salmeterol group than in the fluticasone-only group (hazard ratio, 0.79; 95% CI, 0.70 to 0.89), with at least one severe asthma exacerbation occurring in 480 of 5834 patients (8%) in the fluticasone-salmeterol group, as compared with 597 of 5845 patients (10%) in the fluticasone-only group (P<0.001).
CONCLUSIONS:
Patients who received salmeterol in a fixed-dose combination with fluticasone did not have a significantly higher risk of serious asthma-related events than did those who received fluticasone alone. Patients receiving fluticasone-salmeterol had fewer severe asthma exacerbations than did those in the fluticasone-only group